<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009852</url>
  </required_header>
  <id_info>
    <org_study_id>201309076RIN</org_study_id>
    <nct_id>NCT02009852</nct_id>
  </id_info>
  <brief_title>The Role of microRNA-29b in the Oral Squamous Cell Carcinoma</brief_title>
  <acronym>microRNA-29b</acronym>
  <official_title>The Role of microRNA-29b in the Oral Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Role of microRNA-29b in the Oral Squamous Cell Carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To find out if there is prognostic value which to the performance of microRNA-29b of oral
      cancer in Taiwan and provide some reference for future treatment.

      We anticipate to enroll 100 persons with oral cancer and collect the tissue which was stained
      for pathological sections over a 3 year period.

      We also collect the blood and saliva samples from patients and the results along with
      patient-specific information such as tumor phases, tumor size, lymph node metastasis, cancer
      metastasis, prognosis and betel nut chewing, smoking and drinking habits and other parameters
      are statistically analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>microRNA-29b</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Oral Cancer</condition>
  <arm_group>
    <arm_group_label>Oral cancer</arm_group_label>
    <description>Subjects who suffer from oral cancer.
Subjects must:
Should have a blood exam (20ml/each time) before the surgery and 3 months after the surgery.
In the case the disease recurs after the surgery, subjects need to receive the surgery again and take another blood exam before the surgery and 3 months after the surgery.
Before the surgery site staff must:
Collect subjects' saliva once a day (in the morning before breakfast) for 3 consecutive days.
Collect a 0.5x0.5Cm2 tissue sample of the tumor during the surgery.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      tissue, serum, saliva
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Medical center
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cancer of the oral cavity.

        Exclusion Criteria:

          -  pregnant woman

          -  refuse the surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
    <phone>+886 2 29251733</phone>
    <phone_ext>67509</phone_ext>
    <email>sjcheng56@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital research Ethics Committee</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shin-Jung Cheng, 10048</last_name>
      <phone>+886 2 29251733</phone>
      <phone_ext>67509</phone_ext>
      <email>sjcheng56@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Shin-Jung Cheng, DDS, MS, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>Ambros V. The functions of animal microRNAs. Nature. 2004 Sep 16;431(7006):350-5. Review.</citation>
    <PMID>15372042</PMID>
  </reference>
  <reference>
    <citation>Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H, Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD, Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007 Oct 2;104(40):15805-10. Epub 2007 Sep 21.</citation>
    <PMID>17890317</PMID>
  </reference>
  <reference>
    <citation>Pigazzi M, Manara E, Baron E, Basso G. miR-34b targets cyclic AMP-responsive element binding protein in acute myeloid leukemia. Cancer Res. 2009 Mar 15;69(6):2471-8. doi: 10.1158/0008-5472.CAN-08-3404. Epub 2009 Mar 3.</citation>
    <PMID>19258499</PMID>
  </reference>
  <reference>
    <citation>Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J, Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele J, Weinberg RA. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol. 2010 Mar;12(3):247-56. doi: 10.1038/ncb2024. Epub 2010 Feb 21.</citation>
    <PMID>20173740</PMID>
  </reference>
  <reference>
    <citation>Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007 Oct 11;449(7163):682-8. Epub 2007 Sep 26. Erratum in: Nature. 2008 Sep 11;455(7210):256.</citation>
    <PMID>17898713</PMID>
  </reference>
  <reference>
    <citation>Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, Stephens R, Caplen NJ. MicroRNAs and genomic instability. Semin Cancer Biol. 2007 Feb;17(1):65-73. Epub 2006 Oct 26. Review.</citation>
    <PMID>17113784</PMID>
  </reference>
  <reference>
    <citation>Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. N Engl J Med. 1993 Jan 21;328(3):184-94. Review.</citation>
    <PMID>8417385</PMID>
  </reference>
  <reference>
    <citation>Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003 Jun;3(6):453-8. doi: 10.1038/nrc1098. Review.</citation>
    <PMID>12778135</PMID>
  </reference>
  <reference>
    <citation>Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006 Aug;12(8):895-904. Review.</citation>
    <PMID>16892035</PMID>
  </reference>
  <reference>
    <citation>Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell. 2006 Nov 17;127(4):679-95. Review.</citation>
    <PMID>17110329</PMID>
  </reference>
  <reference>
    <citation>Sciumè G, Soriani A, Piccoli M, Frati L, Santoni A, Bernardini G. CX3CR1/CX3CL1 axis negatively controls glioma cell invasion and is modulated by transforming growth factor-β1. Neuro Oncol. 2010 Jul;12(7):701-10. doi: 10.1093/neuonc/nop076. Epub 2010 Feb 8.</citation>
    <PMID>20511186</PMID>
  </reference>
  <reference>
    <citation>Kok SH, Hong CY, Lin SK, Lee JJ, Chiang CP, Kuo MY. Establishment and characterization of a tumorigenic cell line from areca quid and tobacco smoke-associated buccal carcinoma. Oral Oncol. 2007 Aug;43(7):639-47. Epub 2006 Oct 25.</citation>
    <PMID>17070096</PMID>
  </reference>
  <reference>
    <citation>Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin. 2002 Jul-Aug;52(4):195-215. Review.</citation>
    <PMID>12139232</PMID>
  </reference>
  <reference>
    <citation>Chang CC, Lin MT, Lin BR, Jeng YM, Chen ST, Chu CY, Chen RJ, Chang KJ, Yang PC, Kuo ML. Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. J Natl Cancer Inst. 2006 Jul 19;98(14):984-95.</citation>
    <PMID>16849681</PMID>
  </reference>
  <reference>
    <citation>Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009 Jan 23;136(2):215-33. doi: 10.1016/j.cell.2009.01.002. Review.</citation>
    <PMID>19167326</PMID>
  </reference>
  <reference>
    <citation>Erreni M, Solinas G, Brescia P, Osti D, Zunino F, Colombo P, Destro A, Roncalli M, Mantovani A, Draghi R, Levi D, Rodriguez Y Baena R, Gaetani P, Pelicci G, Allavena P. Human glioblastoma tumours and neural cancer stem cells express the chemokine CX3CL1 and its receptor CX3CR1. Eur J Cancer. 2010 Dec;46(18):3383-92. doi: 10.1016/j.ejca.2010.07.022. Epub 2010 Aug 19.</citation>
    <PMID>20728344</PMID>
  </reference>
  <reference>
    <citation>Gaudin F, Nasreddine S, Donnadieu AC, Emilie D, Combadière C, Prévot S, Machelon V, Balabanian K. Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer. PLoS One. 2011;6(7):e21546. doi: 10.1371/journal.pone.0021546. Epub 2011 Jul 7.</citation>
    <PMID>21750716</PMID>
  </reference>
  <reference>
    <citation>Shiraishi K, Fukuda S, Mori T, Matsuda K, Yamaguchi T, Tanikawa C, Ogawa M, Nakamura Y, Arakawa H. Identification of fractalkine, a CX3C-type chemokine, as a direct target of p53. Cancer Res. 2000 Jul 15;60(14):3722-6.</citation>
    <PMID>10919640</PMID>
  </reference>
  <reference>
    <citation>Moutasim KA, Jenei V, Sapienza K, Marsh D, Weinreb PH, Violette SM, Lewis MP, Marshall JF, Fortune F, Tilakaratne WM, Hart IR, Thomas GJ. Betel-derived alkaloid up-regulates keratinocyte alphavbeta6 integrin expression and promotes oral submucous fibrosis. J Pathol. 2011 Feb;223(3):366-77. doi: 10.1002/path.2786. Epub 2010 Oct 25.</citation>
    <PMID>21171082</PMID>
  </reference>
  <reference>
    <citation>Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell. 2009 Nov 25;139(5):871-90. doi: 10.1016/j.cell.2009.11.007. Review.</citation>
    <PMID>19945376</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microRNA-29b</keyword>
  <keyword>Oral squamous cell carcinoma</keyword>
  <keyword>migration</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

